Alastair Robertson
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adrenergic beta-Antagonists | 9 | 2012 | 321 | 0.590 |
Why?
| Propanolamines | 7 | 2012 | 97 | 0.500 |
Why?
| Receptors, Adrenergic, alpha-2 | 3 | 2012 | 17 | 0.280 |
Why?
| Heart Failure | 11 | 2012 | 2135 | 0.280 |
Why?
| Receptors, Adrenergic, beta-1 | 2 | 2012 | 46 | 0.200 |
Why?
| Heart-Assist Devices | 1 | 2008 | 539 | 0.200 |
Why?
| Heart Transplantation | 1 | 2008 | 721 | 0.190 |
Why?
| Enoximone | 3 | 2007 | 17 | 0.180 |
Why?
| Cardiotonic Agents | 3 | 2007 | 126 | 0.170 |
Why?
| Polymorphism, Genetic | 3 | 2012 | 639 | 0.170 |
Why?
| Survival Rate | 5 | 2010 | 1869 | 0.100 |
Why?
| Torsades de Pointes | 2 | 2003 | 22 | 0.100 |
Why?
| Norepinephrine | 2 | 2012 | 210 | 0.100 |
Why?
| Ventricular Fibrillation | 1 | 2012 | 57 | 0.100 |
Why?
| Anti-Arrhythmia Agents | 1 | 2012 | 111 | 0.100 |
Why?
| Methadone | 2 | 2003 | 91 | 0.090 |
Why?
| Tachycardia, Ventricular | 1 | 2012 | 167 | 0.090 |
Why?
| Clinical Trials Data Monitoring Committees | 1 | 2010 | 6 | 0.090 |
Why?
| Hospital Records | 1 | 2010 | 11 | 0.090 |
Why?
| Cardiomyopathy, Dilated | 2 | 2003 | 381 | 0.080 |
Why?
| Research Personnel | 1 | 2010 | 155 | 0.080 |
Why?
| Middle Aged | 14 | 2012 | 31090 | 0.070 |
Why?
| Ventricular Function, Right | 2 | 2006 | 276 | 0.060 |
Why?
| Hemodynamics | 4 | 2006 | 1090 | 0.060 |
Why?
| Ventricular Function | 1 | 2006 | 61 | 0.060 |
Why?
| Myocardial Contraction | 1 | 2007 | 335 | 0.060 |
Why?
| Metoprolol | 2 | 2002 | 39 | 0.060 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2005 | 93 | 0.060 |
Why?
| Stroke Volume | 4 | 2012 | 592 | 0.060 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2005 | 89 | 0.060 |
Why?
| Carbazoles | 2 | 2002 | 84 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2012 | 1365 | 0.060 |
Why?
| Male | 18 | 2012 | 63512 | 0.060 |
Why?
| Ventricular Function, Left | 3 | 2012 | 527 | 0.050 |
Why?
| Nuclear Lamina | 1 | 2003 | 10 | 0.050 |
Why?
| Hospitalization | 2 | 2010 | 2052 | 0.050 |
Why?
| Female | 17 | 2012 | 68551 | 0.050 |
Why?
| Hypertension, Pulmonary | 2 | 2006 | 1894 | 0.050 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2003 | 52 | 0.050 |
Why?
| Dobutamine | 1 | 2002 | 37 | 0.050 |
Why?
| Long QT Syndrome | 1 | 2003 | 67 | 0.050 |
Why?
| Treatment Outcome | 7 | 2012 | 10202 | 0.050 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 132 | 0.050 |
Why?
| Gene Expression Profiling | 2 | 2006 | 1688 | 0.050 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2003 | 117 | 0.050 |
Why?
| Retrospective Studies | 6 | 2012 | 14461 | 0.050 |
Why?
| Receptors, Adrenergic, beta | 1 | 2002 | 127 | 0.050 |
Why?
| Gene Expression | 2 | 2006 | 1466 | 0.040 |
Why?
| Mutation, Missense | 1 | 2003 | 317 | 0.040 |
Why?
| Oxygen Consumption | 1 | 2004 | 672 | 0.040 |
Why?
| Humans | 19 | 2012 | 129266 | 0.040 |
Why?
| Myocytes, Cardiac | 1 | 2003 | 499 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 3 | 2007 | 2011 | 0.030 |
Why?
| Myocardium | 1 | 2002 | 978 | 0.030 |
Why?
| Adult | 9 | 2012 | 35495 | 0.030 |
Why?
| Aged | 7 | 2012 | 22032 | 0.030 |
Why?
| Multivariate Analysis | 2 | 2012 | 1497 | 0.030 |
Why?
| Double-Blind Method | 2 | 2012 | 1875 | 0.030 |
Why?
| Analgesics, Opioid | 1 | 2002 | 909 | 0.030 |
Why?
| Heart Ventricles | 2 | 2012 | 781 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2003 | 2276 | 0.030 |
Why?
| Administration, Oral | 2 | 2007 | 785 | 0.030 |
Why?
| Homozygote | 1 | 2012 | 193 | 0.020 |
Why?
| Area Under Curve | 1 | 2012 | 304 | 0.020 |
Why?
| Heterozygote | 1 | 2012 | 272 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2012 | 514 | 0.020 |
Why?
| Follow-Up Studies | 3 | 2007 | 4887 | 0.020 |
Why?
| Phenotype | 3 | 2006 | 3074 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2012 | 172 | 0.020 |
Why?
| Aged, 80 and over | 3 | 2009 | 7055 | 0.020 |
Why?
| Bayes Theorem | 1 | 2012 | 373 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2012 | 851 | 0.020 |
Why?
| Polymerase Chain Reaction | 2 | 2003 | 1036 | 0.020 |
Why?
| Electrocardiography | 2 | 2003 | 608 | 0.020 |
Why?
| Genotype | 2 | 2003 | 1835 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2007 | 55 | 0.020 |
Why?
| Prognosis | 2 | 2007 | 3773 | 0.020 |
Why?
| Logistic Models | 1 | 2012 | 1985 | 0.020 |
Why?
| Psychological Tests | 1 | 2007 | 134 | 0.020 |
Why?
| Pain | 2 | 2003 | 786 | 0.020 |
Why?
| Health Status Indicators | 1 | 2007 | 167 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2007 | 399 | 0.020 |
Why?
| Chronic Disease | 2 | 2002 | 1716 | 0.020 |
Why?
| Hospital Mortality | 1 | 2010 | 846 | 0.020 |
Why?
| United States | 3 | 2010 | 13826 | 0.020 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2005 | 72 | 0.020 |
Why?
| Health Surveys | 1 | 2007 | 493 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2007 | 768 | 0.020 |
Why?
| Models, Biological | 1 | 2012 | 1722 | 0.020 |
Why?
| Statistics as Topic | 1 | 2006 | 307 | 0.010 |
Why?
| Cardiomegaly | 1 | 2006 | 172 | 0.010 |
Why?
| RNA, Messenger | 2 | 2003 | 2703 | 0.010 |
Why?
| Severity of Illness Index | 2 | 2003 | 2740 | 0.010 |
Why?
| Multicenter Studies as Topic | 1 | 2005 | 285 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 947 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 756 | 0.010 |
Why?
| Psychometrics | 1 | 2007 | 691 | 0.010 |
Why?
| Hypokalemia | 1 | 2003 | 24 | 0.010 |
Why?
| Radionuclide Angiography | 1 | 2002 | 5 | 0.010 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 110 | 0.010 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2003 | 55 | 0.010 |
Why?
| Angiotensin II | 1 | 2003 | 95 | 0.010 |
Why?
| Calcium-Transporting ATPases | 1 | 2002 | 40 | 0.010 |
Why?
| Heroin Dependence | 1 | 2002 | 31 | 0.010 |
Why?
| Feasibility Studies | 1 | 2006 | 867 | 0.010 |
Why?
| Ventricular Myosins | 1 | 2002 | 36 | 0.010 |
Why?
| Probability | 1 | 2003 | 305 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2003 | 420 | 0.010 |
Why?
| DNA Mutational Analysis | 1 | 2003 | 385 | 0.010 |
Why?
| Pedigree | 1 | 2003 | 486 | 0.010 |
Why?
| Canada | 1 | 2002 | 350 | 0.010 |
Why?
| Cadherins | 1 | 2003 | 188 | 0.010 |
Why?
| Drug Interactions | 1 | 2002 | 393 | 0.010 |
Why?
| Adolescent | 3 | 2006 | 20313 | 0.010 |
Why?
| Myosin Heavy Chains | 1 | 2002 | 170 | 0.010 |
Why?
| Pulmonary Circulation | 1 | 2003 | 430 | 0.010 |
Why?
| Prospective Studies | 1 | 2012 | 7123 | 0.010 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2003 | 580 | 0.010 |
Why?
| Exercise Test | 1 | 2004 | 612 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 2004 | 1197 | 0.010 |
Why?
| Blotting, Western | 1 | 2003 | 1204 | 0.010 |
Why?
| Research Design | 1 | 2005 | 1043 | 0.010 |
Why?
| Drug Therapy, Combination | 1 | 2002 | 1040 | 0.010 |
Why?
| Mass Spectrometry | 1 | 2003 | 713 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2003 | 2056 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2003 | 1691 | 0.010 |
Why?
| Child, Preschool | 2 | 2003 | 10459 | 0.010 |
Why?
| Prevalence | 1 | 2003 | 2553 | 0.010 |
Why?
| Opioid-Related Disorders | 1 | 2003 | 483 | 0.010 |
Why?
| Cell Differentiation | 1 | 2003 | 1887 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2007 | 5384 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2006 | 3386 | 0.010 |
Why?
| Risk Assessment | 1 | 2003 | 3232 | 0.010 |
Why?
| Cohort Studies | 1 | 2003 | 5409 | 0.010 |
Why?
| Time Factors | 1 | 2002 | 6543 | 0.010 |
Why?
| Infant, Newborn | 1 | 2003 | 5736 | 0.010 |
Why?
| Infant | 1 | 2003 | 8975 | 0.000 |
Why?
| Risk Factors | 1 | 2002 | 9745 | 0.000 |
Why?
| Child | 1 | 2003 | 20785 | 0.000 |
Why?
|
|
Robertson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|